Enzyme immunoassays (EIAs) to detect and quantify antibodies against respiratory syncytial virus (RSV) and RSV proteins in human plasma or sera are described. The fi rst EIA uses RSV lysate antigens produced in HEp-2 cell line. The second EIA uses RSV F or G gene-expressed antigen in HEp-2 cells. The third EIA uses 30-amino acid synthetic peptides from central conserved region of G protein of RSV A2 or RSV B1 virus and a peptide from the SARS CoV nucleoprotein as a negative control peptide. All three EIAs have been evaluated for detecting and quantifying the respective antibodies in human sera or plasma.
Introduction
Antibodies against RSV proteins play an important role in preventing disease with RSV by various mechanisms including virus neutralization , antibody-dependent cellular cytotoxicity (ADCC) , and complement-mediated neutralization. The RSV attachment (G) and fusion (F) proteins are the major targets of RSV-specifi c neutralizing antibodies but antibodies against other virus proteins are also induced by infection and can contribute to serological diagnosis of infection. EIA detects both neutralizing and non-neutralizing antibodies and use of RSV lysate antigen in EIA provides a way to detect antibodies against multiple RSV proteins. Use of F or G gene-expressed antigens, e.g., in a HEp-2 cell line, can be used to determine protein-specifi c antibody response. The 30-amino acid synthetic peptides are from a region of the G protein that is immune active and antibodies to this region can prevent some aspects of RSV disease.
14. Goat anti-RSV polyclonal serum (AB1128, Millipore Inc., USA).
15. Anti-goat IgG-HRP-labeled secondary antibody of choice. 4. EIA coating buffer.
5. 50 mL Conical tubes.
6. RSV G protein and SARS CoV N protein peptides ( see Table 1 ).
7. Fluid reservoirs.
Methods
The RSV lysate antigen -based enzyme immunoassay (EIA) detects antibodies against RSV proteins present in preparation including anti-F, anti-G, and anti-N protein antibodies. The EIA can be 2. 3. Thaw the RSV virus stock to use on ice. Once thawed, dilute virus in SF-MEM to achieve 1 × 10 5 pfu/mL (MOI = 0.1).
4. Infect the HEp-2 cells with 3 mL of diluted virus and incubate at 37 °C in 5 % CO 2 for 2 h by rocking every 15 min to spread the virus inoculum on the cell monolayer. For the fl asks that will be used to produce HEp-2 lysate antigen control use 3 mL of SF-MEM instead (mock infection).
5. Remove the inoculums and wash cells thrice with 5 mL of SF-MEM medium.
6. Add 40 mL 5 % FBS-MEM and incubate fl asks at 37 °C in 5 % CO 2 for 72 h.
7. On day 3 (72 h) post-infection, when viral cytopathic effects (CPE) are fi rst becoming evident, remove culture medium and wash the fl ask thrice with 5 mL of SF-MEM ( see Note 3 ).
8. Add 30 mL fresh SF-MEM and incubate the fl ask at 37 °C/5 % CO 2 for further 24-48 h.
9. On days 4-5 post-infection, when 90 % viral ) CPE is observed, freeze the 175 cm 2 fl asks at −80 °C.
10. Thaw the fl asks, remove 2 mL of the virus fl uid from each fl ask, and pool in a 15 mL tube. Subdivide into 0.5 mL aliquots in cryovials, snap freeze using liquid nitrogen, and then store at −80 °C for 24 h. Refreeze the 175 cm 2 fl asks at −80 °C until determination of virus titer.
11. Take out one cryovial that has been frozen at −80 °C for 24 h and perform a plaque assay ( see Chapter 3 ) to determine virus titer.
12. Thaw, freeze, and thaw the 175 cm 2 fl ask to lyse the cells, and then immediately after the third thaw transfer the cell lysate to 50 mL conical tubes. Centrifuge the cell lysate at 1880 × g for 20 min at 4 °C. Aliquot the supernatant in 1.5 mL into cryovials and store at −80 °C.
Production of RSV Virus and HEp-2 Lysate Antigens
1. Perform serial twofold dilutions (1:2 to 1:256) of the RSV lysate EIA and HEp-2 cell lysate in EIA coating buffer.
2. Dispense 100 μL of diluted antigen solution in each column of 96-well EIA plate using multichannel pipette. Seal the plate with adhesive plastic sheet and incubate 37 °C for 2 h and then at 4 °C for 16 h.
3. Remove the lysate antigen and wash fi ve times with 300 μL of EIA washing buffer using an automated plate washer or by hand pipetting up and down.
4. Dry the plates by blotting on paper towel at the end of washing but not between washes.
5. Dispense 200 μL of EIA blocking buffer per well, seal the plates with adhesive plastic sheet, and incubate at 37 °C for 1 h.
6. Wash fi ve times with 300 μL of EIA washing buffer.
7. Dilute goat anti-RSV polyclonal serum in EIA blocking buffer, add 100 μL per well, and incubate for 1 h at 37 °C.
8. Wash fi ve times with 300 μL of EIA washing buffer.
9. Dilute anti-goat IgG-HRP-labeled secondary antibody in EIA blocking buffer. Add 100 μL per well and incubate at 37 °C for 1 h.
10. Wash fi ve times with 300 μL of EIA washing buffer and blot the plates on paper towel at the end of washing.
11. Add 100 μL of OPD substrate per well and incubate the plate for 30 min in the dark at room temperature.
12. Stop the reaction by adding 50 μL of 4 N H 2 SO 4 and gently rock the plate to mix it.
13. Read absorbance at 490 nm within 10-15 min of stopping the EIA reaction.
14. Data analysis can be performed on Microsoft Excel or similar software.
15. Report the highest dilution of RSV lysate antigen that gives corrected (RSV antigen-HEp-2 control antigen) absorbance >1.5 at 490 nm to be used in the subsequent assays. 5. Wash fi ve times with 300 μL of EIA washing buffer using an automated plate washer or by hand pipetting up and down.
6. Dry the plates by blotting on paper towels at the end of washing but not between washes.
7. Dispense 200 μL of EIA blocking buffer per well, seal the plates with adhesive plastic sheet, and incubate at 37 °C for 1 h.
8. Wash fi ve times with 300 μL of EIA washing buffer and dry the plates by blotting on paper towels at the end of washing but not between washes.
9. Dilute human plasma samples in EIA blocking buffer to 1:200 dilution in triplicate, dilute the human reference antiserum to 1:200, and perform serial fourfold dilutions (Fig. 1 ) .
10. Add 100 μL of diluted samples per well and incubate for 1 h at 37 °C.
11. Wash fi ve times with 300 μL of EIA washing buffer and dry the plates by blotting on paper towel at the end of washing but not between washes.
12. Dilute the goat-anti-human IgG-HRP-labeled secondary antibody in EIA blocking buffer. Add 100 μL per well and incubate at 37 °C for 1 h ( see Note 4 ).
13. Wash fi ve times with 300 μL of EIA washing buffer and dry the plates by blotting on paper towels.
14. Add 100 μL of OPD substrate per well and incubate the plate for 30 min in the dark at room temperature.
15. Stop the reaction by adding 50 μL of 4 N H 2 SO 4 and gently rock the plate to mix it.
Human reference antiserum to RSV Plasma sample # 1 1. In a 96-well culture plate seed 2 × 10 4 HEp-2 cells/well in 100 μL of complete medium and incubate at 37 °C in 5 % CO 2 for 18-24 h.
2. Prepare the transfection complexes by mixing the mammalian expression plasmid containing the RSV F or G gene and the transfection reagent of choice. Avalanche ® -Omni transfection reagent will be used as an example for this protocol.
3. In a 15 mL conical tube add 11 μg of DNA into 1250 μL of Opti-MEM ® Reduced-Serum medium or regular high-glucose DMEM without serum ( see Note 6 ). Mix by vortexing.
Briefl y vortex Avalanche
® -Omni and add 11 μL into the 15 mL conical tube containing the DNA. Mix by inversion 8-10 times and incubate for 15 min at room temperature.
5. Add 9.75 mL of complete medium to the 15 mL conical tube containing the transfection complexes and mix by inversion 8-10 times. 13. Wash fi ve times with 300 μL of EIA washing buffer using an automated plate washer or by hand pipetting up and down. Blot the plates on paper towel at the end of washing.
14. In triplicate wells, add 100 μL of test plasma or serum diluted in EIA blocking buffer at a fi nal dilution of 1:200, and incubate the plate at 37 °C for 1 h.
15. Wash fi ve times with 300 μL of EIA washing buffer.
16. Dilute the goat-anti-human IgG-HRP-labeled secondary antibody in EIA blocking buffer, dispense 100 μL per well, and incubate at 37° for 1 h.
17. Wash fi ve times with 300 μL of EIA washing buffer.
18. Add 100 μL of OPD substrate to each well and incubate the plate for 20 min in the dark at room temperature. 21. Data analysis can be performed on Microsoft Excel or similar software ( see Fig. 2 and Note 8 ).
1. Using sterile 50 mL conical tubes dilute RSV A2, RSV B1, and SARS peptide to 5000 ng/mL in EIA coating buffer. Mix fi ve times by vortexing with 5-min intervals in between each vortex until completely dissolved.
2. Transfer peptides to separate fl uid reservoirs.
3. Dispense 100 μL of diluted peptide solution in each column of 96-well EIA plate using a multichannel pipette as per the assay design plate layout ( see Fig. 3 and Note 10 ) 7. Wash fi ve times with 300 μL of EIA washing buffer using an automated plate washer or by hand pipetting up and down. Blot the plates on paper towel at the end of washing.
8. In triplicate wells, add 100 μL of test plasma or serum diluted in EIA blocking buffer at a fi nal dilution of 1:200 and incubate the plate at 37 °C for 1 h.
9. Wash fi ve times with 300 μL of EIA washing buffer using an automated plate washer or by hand pipetting up and down. Blot the plates on paper towel at the end of washing.
10. Dilute the goat-anti-human IgG-HRP-labeled secondary antibody in EIA blocking buffer, dispense 100 μL per well, and incubate at 37 °C for 1 h.
11. Wash fi ve times with 300 μL of EIA washing buffer. Blot the plates on paper towel at the end of washing.
12. Add 100 μL of OPD substrate to each well and incubate the plate for 20 min in the dark at room temperature. 14. Read optical density/absorbance at 490 nm within 10-15 min of stopping the EIA reaction.
15. Data analysis can be performed on Microsoft Excel or similar software ( see Note 11 ).
Notes
1. To dissolve paraformaldehyde in water add 1 M NaOH and stir gently on a heating block at 60 °C until the PFA is dissolved. Add 10 mL of 10× PBS and allow the mixture to cool to room temperature. Adjust the pH to 7.4 with 1 M HCl (~1 mL), and then adjust the fi nal volume to 100 mL with H 2 O. Filter the solution through a 0.45 μm membrane fi lter to remove any particulate matter 2. The HEp-2 cell culture is grown in 175 cm 2 vented cell culture fl ask and should be processed in a separate hood for mock infection. The HEp-2 cell lysate should be prepared as described for RSV lysate antigen production and 5 % FBS-MEM replaced by SF-MEM at comparable times.
3. The RSV virus CPE is characterized by formation of syncytia, formation of giant cells, and rounding and sloughing of HEp-2 cells . The CPE can be observed using an inverted microscope at 40-100× magnifi cation. The uninfected HEp-2 cells that will be used for HEp-2 lysate antigen control should not present any CPE.
4. Follow the manufacturer's recommendation to determine the dilution of secondary antibody. Approximately 10 mL of diluted conjugate is used for one plate. Scale up or down according to the number of plates being tested.
5. Data analysis can be performed using a standard curve generated for serial twofold dilutions of a human reference antiserum to RSV (available from NIH BEI Resources, USA, Cat # NR-4020) and predict the end point antibody titers in test plasma/serum samples.
6. As a negative control we recommend to use the empty vector lacking of the RSV F and G gene.
7. After this step the plates can be stored for up to 2 weeks in ziplock bags at 4 °C for further use. Before storage, the individual plates should be sealed with adhesive plastic sheet.
8. Final data can be presented as positive or negative for RSV antibodies (absorbance against F-or G-transfected cells (P) signifi cantly above those for plasmid control (N)) and antibody titer for positive specimens. The titer of RSV antibody can be estimated by comparing corrected absorbance values (P-N) for the specimen to those for serial twofold dilutions of the human reference antiserum to RSV (available from NIH BEI Resources Cat # NR-4020, USA) or an RSV antibody high positive plasma from a donor.
9. This assay is developed to detect human anti-RSV group A and B antibodies to the central conserved region of glycoprotein. Peptides of 30 amino acid length are custom synthesized at 75 % or higher purity ( see Table 1 ). A standard high-titer serum specimen with reactivity to RSV G peptides should be used to monitor consistency and quality of results. Seven plasma specimens can be tested at one dilution (dilution 1:200) against RSV G peptide and control peptide in one ELISA plate. The SARS CoV nucleoprotein peptide 1-30 amino acid (30 mer) is used as a negative control peptide.
10. Two plate layouts are used, one that includes serial twofold dilutions of the serum standard to generate a standard curve and the other plates that allows testing seven plasma/serum specimens at a 1:200 dilution. Each dilution or specimen is tested in triplicate wells for RSV peptide and SARS control peptide.
11. Data analysis can be performed by plotting standard curve for the twofold dilution of standard reference positive plasma or serum sample using Microsoft Excel. The prediction of the antibody titers in test plasma/serum samples can be determined using the standard curve.
